PT3266456T - Métodos de tratamento de cancro pancreático utilizando terapias de associação que compreendem irinotecano lipossómico - Google Patents
Métodos de tratamento de cancro pancreático utilizando terapias de associação que compreendem irinotecano lipossómicoInfo
- Publication number
- PT3266456T PT3266456T PT171690985T PT17169098T PT3266456T PT 3266456 T PT3266456 T PT 3266456T PT 171690985 T PT171690985 T PT 171690985T PT 17169098 T PT17169098 T PT 17169098T PT 3266456 T PT3266456 T PT 3266456T
- Authority
- PT
- Portugal
- Prior art keywords
- leucovorin
- combinations
- treatment
- pancreatic cancer
- liposomal irinotecan
- Prior art date
Links
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title 1
- 235000008191 folinic acid Nutrition 0.000 title 1
- 239000011672 folinic acid Substances 0.000 title 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 229960001691 leucovorin Drugs 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659211P | 2012-06-13 | 2012-06-13 | |
| US201361784382P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3266456T true PT3266456T (pt) | 2021-07-28 |
Family
ID=48692681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171690985T PT3266456T (pt) | 2012-06-13 | 2013-06-12 | Métodos de tratamento de cancro pancreático utilizando terapias de associação que compreendem irinotecano lipossómico |
| PT137312302T PT2861210T (pt) | 2012-06-13 | 2013-06-12 | Métodos de tratamento de cancro pancreático utilizando terapias de associação que compreendem irinotecano lipossómico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137312302T PT2861210T (pt) | 2012-06-13 | 2013-06-12 | Métodos de tratamento de cancro pancreático utilizando terapias de associação que compreendem irinotecano lipossómico |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US9452162B2 (enExample) |
| EP (3) | EP2861210B1 (enExample) |
| JP (3) | JP6310911B2 (enExample) |
| KR (3) | KR101776808B1 (enExample) |
| CN (2) | CN104717961A (enExample) |
| AU (3) | AU2013202947B2 (enExample) |
| BR (1) | BR112014031088A8 (enExample) |
| CA (1) | CA2875824C (enExample) |
| DK (2) | DK2861210T3 (enExample) |
| ES (2) | ES2880089T3 (enExample) |
| IL (3) | IL235937B (enExample) |
| IN (1) | IN2014DN11099A (enExample) |
| MX (1) | MX376937B (enExample) |
| NZ (1) | NZ702469A (enExample) |
| PL (2) | PL2861210T3 (enExample) |
| PT (2) | PT3266456T (enExample) |
| RU (1) | RU2663450C2 (enExample) |
| SI (2) | SI3266456T1 (enExample) |
| TW (3) | TW201831168A (enExample) |
| WO (1) | WO2013188586A1 (enExample) |
| ZA (1) | ZA201408804B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2424792C2 (ru) * | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| CA2934552C (en) * | 2014-01-14 | 2021-03-30 | Nektar Therapeutics | Combination-based treatment method |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| JP7113619B2 (ja) * | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
| TW201701880A (zh) * | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| TW202126293A (zh) * | 2015-08-21 | 2021-07-16 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| DK3349731T3 (da) * | 2015-09-16 | 2024-01-08 | Univ Texas | Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft |
| CA3001467A1 (en) | 2015-10-16 | 2017-04-20 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| UA125646C2 (uk) * | 2016-05-18 | 2022-05-11 | Іпсен Біофарм Лтд. | Лікування дрібноклітинного раку легенів за допомогою ліпосомального іринотекану |
| JP2019533684A (ja) * | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
| IL308722B2 (en) * | 2018-10-17 | 2025-01-01 | Biolinerx Ltd | Treatment of metastatic pancreatic adenocarcinoma |
| US20220072087A1 (en) * | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| US11286344B2 (en) | 2020-01-10 | 2022-03-29 | Tyndall Formulation Services, LLC | Polymer excipients for drug delivery applications |
| US11857630B2 (en) | 2020-01-10 | 2024-01-02 | Tyndall Formulation Services, LLC | Formulations of SN-38 with poly(amino acid) block polymers |
| US11478505B2 (en) | 2020-01-10 | 2022-10-25 | R-Pharm Us Operating Llc | Compositions of ixabepilone |
| MX2024003989A (es) * | 2021-10-03 | 2024-04-26 | Systimmune Inc | Metodos de tratamiento del cancer y composiciones farmaceuticas de los mismos. |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2628659A (en) * | 1951-01-17 | 1953-02-17 | Charles R Carpenter | Convertible furniture article |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| AU4990397A (en) | 1996-10-22 | 1998-05-15 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| NZ511112A (en) | 1998-09-16 | 2003-11-28 | Alza Corp | Lipsome-entrapped topoisomerase inhibitors |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| AU2869901A (en) | 2000-02-04 | 2001-08-14 | Lipoxen Technologies Limited | Liposomes |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| NZ522766A (en) | 2000-05-15 | 2005-09-30 | Celgene Corp | Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects |
| AU7038501A (en) | 2000-06-30 | 2002-01-14 | Inex Pharmaceuticals Corp | Liposomal antineoplastic drugs and uses thereof |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| MXPA03008864A (es) | 2001-03-26 | 2004-12-06 | Johnson & Johnson | Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico. |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| EP1408973A2 (en) | 2001-07-23 | 2004-04-21 | Epidauros Biotechnologie AG | Means and methods for improved treatment of cancer based on mrp1 |
| US20030077833A1 (en) * | 2001-09-07 | 2003-04-24 | Queen's University At Kingston | Diagnositc methods for determining susceptibility to convulsive conditions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| ITBO20010610A1 (it) | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
| EP1509203B1 (en) | 2002-05-15 | 2016-04-13 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| EP2182004A1 (en) | 2002-05-31 | 2010-05-05 | Transmolecular, Inc. | Combination therapy of isotopically labelled chlorotoxin with temozolomide |
| WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| RS20160203A1 (sr) | 2003-05-30 | 2016-10-31 | Genentech Inc | Tretman sa anti-vegf antitelima |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| CN1960729B (zh) | 2004-06-01 | 2012-04-11 | 泰尔茂株式会社 | 伊立替康制剂 |
| EP1761264A1 (en) * | 2004-06-03 | 2007-03-14 | F.Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| AU2006306108B2 (en) | 2005-10-25 | 2012-10-04 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| JP2009515884A (ja) * | 2005-11-10 | 2009-04-16 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性の阻害剤 |
| EP1976485A4 (en) * | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF |
| CN101370497B (zh) | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | 包含parp抑制剂和细胞毒性剂的联合产品及用途 |
| CN101442998B (zh) | 2006-03-16 | 2012-03-14 | 比奥纽默里克药物公司 | 抗癌活性加强化合物和制剂及其用法 |
| CN101506362B (zh) * | 2006-11-30 | 2012-09-05 | 爱科来株式会社 | Ugt1a1基因扩增用引物对、含有其的ugt1a1基因扩增用试剂及其用途 |
| EP2647388A1 (en) | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Antibodies Against ERBB3 and Uses Thereof |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| WO2009040426A1 (en) | 2007-09-28 | 2009-04-02 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
| NZ586123A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| EP2224804A4 (en) | 2007-12-07 | 2011-06-01 | Bipar Sciences Inc | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| JP2011515478A (ja) | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | 結腸直腸がんを処置または予防するための方法 |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| PL2288715T3 (pl) | 2008-04-11 | 2015-03-31 | Merrimack Pharmaceuticals Inc | Łączniki będące albuminą surowicy ludzkiej i ich koniugaty |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| RU2496499C2 (ru) * | 2008-09-26 | 2013-10-27 | Эститю Де Кансероложи Де Л'Вест | Оптимизация индивидуальных доз 5-фторурацила при режиме folfiri |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| CN102573826A (zh) | 2009-05-01 | 2012-07-11 | 奥克兹美制药公司 | 用于治疗癌症的喷他脒组合 |
| US20120282325A1 (en) | 2009-12-03 | 2012-11-08 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Liposome of irinotecan or its hydrochloride and preparation method thereof |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| JP2013531069A (ja) | 2010-07-19 | 2013-08-01 | バイパー サイエンシズ，インコーポレイティド | ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法 |
| CA2806076A1 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| WO2012031293A1 (en) | 2010-09-03 | 2012-03-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
| EP2648738A2 (en) | 2010-12-06 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents |
| WO2012079582A1 (en) | 2010-12-14 | 2012-06-21 | Technical University Of Denmark | Entrapment of radionuclides in nanoparticle compositions |
| CA2827118A1 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| CN103703026B (zh) | 2011-04-19 | 2015-08-26 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| EP2838880B1 (en) | 2012-04-17 | 2017-12-13 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| AU2013374248A1 (en) | 2012-12-14 | 2015-06-11 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| TR201819576T4 (tr) | 2013-03-27 | 2019-01-21 | Taiho Pharmaceutical Co Ltd | Düşük Dozda İrinotekan Hidroklorid Hidrat İçeren Antitümör Ajanı |
| US10111871B2 (en) | 2013-08-27 | 2018-10-30 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| WO2015061592A1 (en) | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
| JP7113619B2 (ja) | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
| TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| TW202126293A (zh) | 2015-08-21 | 2021-07-16 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| CA3001467A1 (en) | 2015-10-16 | 2017-04-20 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| UA125646C2 (uk) | 2016-05-18 | 2022-05-11 | Іпсен Біофарм Лтд. | Лікування дрібноклітинного раку легенів за допомогою ліпосомального іринотекану |
| JP2019533684A (ja) | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
-
2013
- 2013-04-08 AU AU2013202947A patent/AU2013202947B2/en active Active
- 2013-06-11 TW TW107116721A patent/TW201831168A/zh unknown
- 2013-06-11 TW TW102120630A patent/TWI630924B/zh active
- 2013-06-11 TW TW108132921A patent/TWI729492B/zh active
- 2013-06-12 CN CN201380036765.4A patent/CN104717961A/zh active Pending
- 2013-06-12 KR KR1020157000450A patent/KR101776808B1/ko active Active
- 2013-06-12 EP EP13731230.2A patent/EP2861210B1/en not_active Revoked
- 2013-06-12 BR BR112014031088A patent/BR112014031088A8/pt not_active Application Discontinuation
- 2013-06-12 EP EP21171689.9A patent/EP3919048A1/en active Pending
- 2013-06-12 ES ES17169098T patent/ES2880089T3/es active Active
- 2013-06-12 IN IN11099DEN2014 patent/IN2014DN11099A/en unknown
- 2013-06-12 PT PT171690985T patent/PT3266456T/pt unknown
- 2013-06-12 CA CA2875824A patent/CA2875824C/en active Active
- 2013-06-12 PL PL13731230T patent/PL2861210T3/pl unknown
- 2013-06-12 PL PL17169098T patent/PL3266456T3/pl unknown
- 2013-06-12 RU RU2015100529A patent/RU2663450C2/ru active
- 2013-06-12 WO PCT/US2013/045495 patent/WO2013188586A1/en not_active Ceased
- 2013-06-12 EP EP17169098.5A patent/EP3266456B1/en active Active
- 2013-06-12 NZ NZ702469A patent/NZ702469A/en unknown
- 2013-06-12 ES ES13731230.2T patent/ES2632915T3/es active Active
- 2013-06-12 IL IL235937A patent/IL235937B/en unknown
- 2013-06-12 KR KR1020197018996A patent/KR20190107010A/ko not_active Withdrawn
- 2013-06-12 DK DK13731230.2T patent/DK2861210T3/en active
- 2013-06-12 CN CN201910188153.6A patent/CN110051631A/zh active Pending
- 2013-06-12 JP JP2015517405A patent/JP6310911B2/ja active Active
- 2013-06-12 US US14/406,776 patent/US9452162B2/en active Active
- 2013-06-12 MX MX2014015391A patent/MX376937B/es active IP Right Grant
- 2013-06-12 PT PT137312302T patent/PT2861210T/pt unknown
- 2013-06-12 SI SI201331912T patent/SI3266456T1/sl unknown
- 2013-06-12 AU AU2013274287A patent/AU2013274287B2/en active Active
- 2013-06-12 KR KR1020177024678A patent/KR101997206B1/ko active Active
- 2013-06-12 SI SI201330697T patent/SI2861210T1/sl unknown
- 2013-06-12 IL IL294886A patent/IL294886A/en unknown
- 2013-06-12 DK DK17169098.5T patent/DK3266456T3/da active
-
2014
- 2014-12-02 ZA ZA2014/08804A patent/ZA201408804B/en unknown
-
2015
- 2015-07-29 US US14/812,950 patent/US9339497B2/en active Active
- 2015-09-03 US US14/844,500 patent/US9364473B2/en active Active
- 2015-09-11 US US14/851,111 patent/US9492442B2/en active Active
-
2016
- 2016-03-03 US US15/059,640 patent/US20160228428A1/en not_active Abandoned
- 2016-11-02 US US15/341,377 patent/US20170065578A1/en not_active Abandoned
-
2017
- 2017-06-08 JP JP2017113465A patent/JP2017149783A/ja not_active Withdrawn
- 2017-07-18 US US15/652,513 patent/US20170368056A1/en not_active Abandoned
-
2018
- 2018-03-19 AU AU2018201942A patent/AU2018201942B2/en active Active
- 2018-06-19 US US16/012,351 patent/US10980795B2/en active Active
-
2019
- 2019-05-07 JP JP2019087488A patent/JP6857210B2/ja active Active
-
2021
- 2021-03-17 US US17/204,278 patent/US20220096458A1/en not_active Abandoned
-
2023
- 2023-07-20 IL IL304631A patent/IL304631A/en unknown
-
2024
- 2024-03-22 US US18/613,609 patent/US20240226090A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3266456T1 (sl) | Kombinacije iz liposomskega irinotekana, 5-FU in levkovorina za zdravljenje raka trebušne slinavke | |
| HUE049129T2 (hu) | Piridopirazin és naftiridin-származékok rák kezelésére | |
| IL238400A (en) | Triazulophyrazines as brd4 inhibitors for use in cancer treatment | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| GB2500588B (en) | Systems and methods of hyperthermal treatment | |
| EP2941421A4 (en) | COUMESTAN, COUMESTROL, COUMESTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | |
| IL238481A0 (en) | Cancer treatment using synthetic lethal approaches | |
| EP2897689A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALOPEZIA | |
| ZA201502009B (en) | Combinations of sglt2 inhibitors and antihypertensive drugs | |
| IL239374B (en) | Preparations and methods for treating brain tumors | |
| ZA201504167B (en) | Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates | |
| ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis | |
| PT2892560T (pt) | Métodos e produtos para prevenção e/ou tratamento do cancro metastático | |
| EP2870133A4 (en) | TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF | |
| GB2507765B (en) | Substituted pyridine derivatives useful in the treatment of cancer | |
| AP3759A (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same | |
| AU2012903874A0 (en) | Methods and products for preventing and/or treating cancer | |
| IL239817A0 (en) | Comstan, Comstrol, their derivatives, processes for their production and their uses | |
| GB201222855D0 (en) | Lock Means and Method of Use Thereof | |
| AU2012902982A0 (en) | Compositions and methods for the treatment of tuberculosis |